DLK1 Antibodies and Methods of Treating Cancer

Antigen binding proteins targeting DLK1 on cancer cells inhibit tumor growth by inducing cytotoxicity, addressing the need for effective, side-effect-minimized cancer therapies.

JP2024546106A5Pending Publication Date: 2026-01-14RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534244
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-07
Filing Date
2022-12-07
Publication Date
2026-01-14

Smart Images

  • Figure 2023107560000001
    Figure 2023107560000001
  • Figure 2023107560000002
    Figure 2023107560000002
  • Figure 2023107560000003
    Figure 2023107560000003
Patent Text Reader

Abstract

The present disclosure provides antigen-binding proteins that bind DLK1, bispecific antigen-binding proteins that bind DLK1 and a second antigen, and conjugates thereof.Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein.Kits and pharmaceutical compositions that include such entities are further provided.Methods for producing antigen-binding proteins and methods for treating subjects with cancer are also provided.
Need to check novelty before this filing date? Find Prior Art